Current Australasian practice for diagnosis and management of idiopathic pulmonary fibrosis: Where are we now?

Respirology

Volumn 20, Issue 4, 2015, Pages 647-653

  Troy, Lauren K ^a,b   Chapman, Sally A ^c,d   Lake, Fiona ^e   Wilsher, Margaret L ^f,g   Honeysett, Liarna B ^a,d   Macansh, Sacha ^d   Corte, Tamera J ^a,b,d  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d Lung Foundation Australia   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f AUCKLAND CITY HOSPITAL   (New Zealand)

^g UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

clinical decision making; disease management; idiopathic pulmonary fibrosis; practice; pulmonary fibrosis

Indexed keywords

AZATHIOPRINE; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTETATE TECHNETIUM TC 99M; PREDNISONE;

ARTERIAL GAS; ARTICLE; AUSTRALIA AND NEW ZEALAND; CARDIOPULMONARY EXERCISE TEST; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ERYTHROCYTE SEDIMENTATION RATE; FIBROSING ALVEOLITIS; FOLLOW UP; HUMAN; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG LAVAGE; LUNG VOLUME; MONOTHERAPY; PATIENT REFERRAL; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PULSE OXIMETRY; QUESTIONNAIRE; RURAL AREA; SPIROMETRY; TEACHING HOSPITAL; THORAX RADIOGRAPHY; TREATMENT RESPONSE; ADULT; AGED; AUSTRALIA; BIOPSY; CLINICAL TRIAL; CONSENSUS; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; FEMALE; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; MULTICENTER STUDY; NEW ZEALAND; PRACTICE GUIDELINE; STANDARDS;

ADULT; AGED; AUSTRALIA; BIOPSY; BRONCHOALVEOLAR LAVAGE; CONSENSUS; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; NEW ZEALAND; PRACTICE GUIDELINES AS TOPIC; RADIOGRAPHY, THORACIC; SURVEYS AND QUESTIONNAIRES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84927725502     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12512     Document Type: Article

References (26)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788-824.
2. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188: 733-748.
3. Flaherty KR, King TE Jr, Raghu G, Lynch JP 3rd, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am. J. Respir. Crit. Care Med. 2004; 170: 904-910.
4. Likert R,. A technique for the measurement of attitudes. Arch. Psychol. 1932; 140: 1-55.
5. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction. Thorax 1999; 54 (Suppl. 1): S1-S28.
6. Flaherty KR, Andrei AC, King TE Jr, Raghu G, Colby TV, Wells A, Bassily N, Brown K, du Bois R, Flint A, et al. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am. J. Respir. Crit. Care Med. 2007; 175: 1054-1060.
7. Shim HS, Park MS, Park IK,. Histopathologic findings of transbronchial biopsy in usual interstitial pneumonia. Pathol. Int. 2010; 60: 373-377.
8. Poletti V, Patelli M, Poggi S, Bertanti T, Spiga L, Ferracini R,. Transbronchial lung biopsy and bronchoalveolar lavage in diagnosis of diffuse infiltrative lung diseases. Respiration 1988; 54 (Suppl. 1): 66-72.
9. Berbescu EA, Katzenstein AL, Snow JL, Zisman DA,. Transbronchial biopsy in usual interstitial pneumonia. Chest 2006; 129: 1126-1131.
10. Veeraraghavan S, Latsi PI, Wells AU, Pantelidis P, Nicholson AG, Colby TV, Haslam PL, Renzoni EA, du Bois RM,. BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur. Respir. J. 2003; 22: 239-244.
11. Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, Hutchinson J, Pardee NE, Winterbauer RH,. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. 1991; 144: 291-296.
12. Johnson MA, Kwan S, Snell NJ, Nunn AJ, Darbyshire JH, Turner-Warwick M,. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280-288.
13. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353: 2229-2242.
14. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ,. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012; 366: 1968-1977.
15. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2005; 171: 1040-1047.
16. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
17. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2011; 365: 1079-1087.
18. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071-2082.
19. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2083-2092.
20. Collard HR, Loyd JE, King TE Jr, Lancaster LH,. Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Respir. Med. 2007; 101: 2011-2016.
21. Macedo P, Coker RK, Partridge MR,. Is there a uniform approach to the management of diffuse parenchymal lung disease (DPLD) in the UK? A national benchmarking exercise. BMC Pulm. Med. 2007; 7: 3.
22. Peikert T, Daniels CE, Beebe TJ, Meyer KC, Ryu JH,. Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis. Respir. Med. 2008; 102: 1342-1348.
23. Flaherty KR, Thwaite EL, Kazerooni EA, Gross BH, Toews GB, Colby TV, Travis WD, Mumford JA, Murray S, Flint A, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003; 58: 143-148.
24. Jegal Y, Kim DS, Shim TS, Lim CM, Do Lee S, Koh Y, Kim WS, Kim WD, Lee JS, Travis WD, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2005; 171: 639-644.
25. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK,. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 538-542.
26. Hallstrand TS, Boitano LJ, Johnson WC, Spada CA, Hayes JG, Raghu G,. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur. Respir. J. 2005; 25: 96-103.